| Literature DB >> 31260518 |
Brett W Jagger1, Kimberly A Dowd2, Rita E Chen1, Pritesh Desai1, Bryant Foreman2, Katherine E Burgomaster2, Sunny Himansu3, Wing-Pui Kong4, Barney S Graham4, Theodore C Pierson2, Michael S Diamond1,5,6,7.
Abstract
Zika virus (ZIKV) caused an epidemic of congenital malformations in 2015-2016. Although many vaccine candidates have been generated, few have demonstrated efficacy against congenital ZIKV infection. Here, we evaluated lipid-encapsulated messenger RNA (mRNA) vaccines and a DNA plasmid vaccine encoding the prM-E genes of ZIKV in mouse models of congenital infection. Although the DNA vaccine provided comparable efficacy against vertical transmission of ZIKV, the mRNA vaccines, including one that minimizes antibody-dependent enhancement of infection, elicited higher levels of antigen-specific long-lived plasma cells and memory B cells. Despite the induction of robust neutralizing antibody titers by all vaccines, breakthrough seeding of the placenta and fetal head was observed in a small subset of type I interferon signaling-deficient immunocompromised dams. In comparison, evaluation of one of the mRNA vaccines in a human STAT2-knockin transgenic immunocompetent mouse showed complete protection against congenital ZIKV transmission. These data will inform ongoing human ZIKV vaccine development efforts and enhance our understanding of the correlates of vaccine-induced protection.Entities:
Keywords: Zika; congenital Zika syndrome; neutralizing antibody; pregnancy; vaccine
Mesh:
Substances:
Year: 2019 PMID: 31260518 PMCID: PMC6782106 DOI: 10.1093/infdis/jiz338
Source DB: PubMed Journal: J Infect Dis ISSN: 0022-1899 Impact factor: 5.226